New hope for anemia patients: drug may cut need for blood transfusions

NCT ID NCT05891249

Ongoing Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called luspatercept in people with anemia caused by myelodysplastic syndromes (MDS) or beta-thalassemia who need regular blood transfusions. The goal is to see if the drug is safe and can reduce the number of transfusions needed. About 85 participants in India will receive the drug and be monitored for side effects and transfusion reduction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anemia beta thalassemia bone marrow disorder hematologic disorder hemoglobin E-beta-thalassemia syndrome inherited hemoglobinopathy myelodysplastic syndrome with ring sideroblasts

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANEMIA

Contacts and locations

Locations

Local Institution - 0001

New Delhi, National Capital Territory of Delhi, 110029, India
Local Institution - 0002

Ahmedabad, Gujarat, 380009, India
Local Institution - 0003

Bangalore, 560027, India
Local Institution - 0004

Chandigarh, 160012, India
Local Institution - 0005

Assam, 781032, India
Local Institution - 0006

Hyderabad, 500034, India
Local Institution - 0007

Kolkata, West Bengal, 700014, India
Local Institution - 0008

Mumbai, 400012, India
Local Institution - 0010

Delhi, 110085, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.